Trial Profile
A Phase 2, Double-Blind, Randomized, Safety Study of GE-145 320 mg I/mL Injection Versus Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Artery Catheterization Procedure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2018
Price :
$35
*
At a glance
- Drugs Ioforminol (Primary) ; Iopamidol
- Indications Coronary artery disease
- Focus Diagnostic use
- Sponsors GE Healthcare
- 27 May 2014 New trial record